Assembly Biosciences, Inc. (NASDAQ: ASMB) is a Healthcare company (Biotechnology) with a market capitalization of $461M. The Maz Rating grades it against the other companies in its sector.
Assembly Biosciences, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $22.50, Assembly Biosciences, Inc. trades at 27.2x trailing earnings, 6.8x sales and 1.6x book value. Over the last twelve months it generated about $68M of revenue and $17M of net income. It runs a gross margin of 99.9%, an operating margin of -31.8% and a net margin of -16.6%. It shows return on equity of -4.4%, return on invested capital of -7.1% and a free cash flow yield of -8.9%. On the balance sheet: a debt-to-equity ratio of 0.01 and a current ratio of 12.89. Over the past 52 weeks the share price ranged from $19.20 to $39.71, with a beta of 1.22.
Assembly Biosciences, Inc. does not currently pay a dividend.
12 Wall Street analyst ratings cover the stock: 7 Buy and 5 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candidate, Vebicorvir, has successfully concluded Phase 2 clinical trials for individuals with chronic HBV. The company's development pipeline also features ABI-H3733, which has finished Phase 1a clinical studies, and ABI-4334, currently in pre-clinical assessment for HBV treatment. Assembly Biosciences has forged collaborative partnerships, including agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation, as well as with Antios Therapeutics, Inc., to explore a triple-combination treatment strategy for chronic hepatitis B virus. Additionally, it maintains strategic licensing arrangements with Indiana University Research and Technology Corporation and Door Pharmaceuticals, LLC. Established in 2005, the company was formerly known as Ventrus Biosciences, Inc. before rebranding to Assembly Biosciences, Inc. in June 2014, and its headquarters are located in South San Francisco, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Assembly Biosciences, Inc. (ASMB) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 64.3% / 30% · Interest income / Revenue 106.9% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 64.3% / 33% · Receivables / Mkt Cap (36m) 0.12% / 49% · Interest income / Revenue 106.9% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 64.3% / 33.33% · Receivables / Mkt Cap (24m) 0.12% / 33.33% · Interest income / Revenue 106.9% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.17% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 96.5% / 33.33% · Receivables / Avg Assets (4Q) 0.25% / 33.33% · Interest income / Revenue 106.9% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 96.6% / 33.33% · (Cash+Recv) / Total Assets 96.8% / 33.33% · Interest income / Revenue 106.9% / 5% | Fail |
No. As of September 2026, Assembly Biosciences, Inc. (ASMB) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Assembly Biosciences, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 106.9% of each dividend: Assembly Biosciences, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.